You are here: Industry Insights > GSK

News List

GSK retains leading position on access to medicines list pharmatimes
November 22, 2018
The 2018 Access to Medicine Index - which measures the performance of the top 20 pharma companies across seven different categories, such as access-to-medicine
GSK's anti-seizure drug shows promise in early depression study pharmafile
November 20, 2018
Researchers have found that GlaxoSmithKline’s ezogabine (Potiga), approved by the FDA in 2011 as an anti-seizure therapy, could have applications as a treatmen
EU expands label of GSK/Innoviva’s COPD inhaler pharmatimes
November 14, 2018
GSK noted that while bronchodilation is recognised as the foundation of COPD therapy, “many patients may continue to struggle with symptoms and exacerbations over time”.
Vectura Group announces global agreement with Hikma to develop generic versions of GSK’s Ellipta® portfolio pharmafocusasia
November 12, 2018
Vectura Group plc, today announces signing an agreement with Hikma Pharmaceuticals PLC ("Hikma") for the global development and commercialisation of generic versions of GSK’s Ellipta® portfolio, utilising Vectura’s proprietary Open-Inhale-Close dry powder
Hikma, Vectura to develop generic rivals to GSK's Ellipta portfolio pharmatimes
November 12, 2018
Following interactions with US regulators, the firms believe the inhaler device has the potential to be developed as a substitutable drug-device combination for generic versions of the GSK Ellipta portfolio.
GSK execs change their tune as AZ, Sanofi heap pressure on respiratory hopeful Nucala fiercepharma
November 11, 2018
On the company’s third-quarter conference call last week, the British drugmaker’s pharma chief, Luke Miels, told investors the company had “very much held” AstraZeneca newcomer Fasenra “in place in Japan and Europe.”
Hikma, Vectura enter deal targeting generic versions of GlaxoSmithKline's Ellipta portfolio firstwordpharma
November 09, 2018
Hikma Pharmaceuticals and Vectura announced Thursday an agreement to develop and market generic versions of GlaxoSmithKline's Ellipta portfolio.
Researchers have found that GlaxoSmithKline’s ezogabine (Potiga), approved by the FDA in 2011 as an anti-seizure therapy, could have applications as a treatment for treatment-resistant depression pharmafile
November 06, 2018
Following its approval in the US, the FDA ordered GSK to conduct additional safety studies after concerns were raised that the drug’s use could affect...
GSK's anti-seizure drug shows promise in early depression study pharmafile
November 05, 2018
Researchers have found that GlaxoSmithKline’s ezogabine (Potiga), approved by the FDA in 2011 as an anti-seizure therapy, could have ....
GSK narrows earnings guidance after Shingrix boost pharmatimes
November 05, 2018
GSK says it now expects full-year earnings at the upper end of its guidance after continued sales growth during the third quarter and the delay to generic

Previous page 1 2 3 4 5 6 7 8 9 10 ... 40 41 Next page